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Abstract: Purpose: The identification of high-risk patients within Human Papillomavirus (HPV) posi-
tive and negative head and neck squamous cell carcinoma patients is needed for improved treatment and
surveillance strategies. In this study, we set out to discover Antibody responses (AR) with prognostic
impact in head and neck squamous cell carcinoma (HNSCC) stratified by HPV-status. Experimental De-
sign: A fluorescent bead-based multiplex serology assay to 29 cancer antigens (16 cancer-testis antigens,
5 cancer-retina antigens, 8 oncogenes) and 29 HPV-antigens was performed in samples of 362 HNSCC
patients from five independent cohorts (153 HPV-positive, 209 HPV-negative). A multivariable cox pro-
portional hazard model with bootstrapping (M=1000) was used for validation of prognostic antibody
responses. Results: AR to any of the cancer antigens were found in 257/362 patients (71%). In HPV-
negative patients, antibody responses to to c-myc, MAGE-A1, -A4 and Rhodopsin E2 (combined as
ARhigh risk) were significantly associated with shorter overall survival. In HPV-positive patients anti-
body responses to IMP-1 were discovered as a negative prognostic factor. ARhigh risk (HR=1.76) and
antibody responses to IMP-1 (HR=3.28) were confirmed as independent markers for a poor prognosis in
a multivariable Cox proportional hazard model with bootstrapping (M=1000). Conclusion: We identified
AR to cancer antigens that associate with a dismal prognosis in HNSCC patients beyond HPV-positive-
status. ARhigh risk may be used to detect HPV-negative patients with an extraordinarily bad prognosis.
Most importantly, AR to IMP-1 may serve as a marker for a subgroup of HPV-positive patients that
present with a poor prognosis similar to that in HPV-negative patients.
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Statement of translational relevance: 
Human Papillomavirus (HPV) driven head and neck squamous cell carcinoma (HNSCC) is 
characterized by a much better prognosis than HPV-negative HNSCC. Recent studies focus 
on de-escalation of treatment. However, among HPV-positive patients, a subgroup with a 
dismal prognosis exists. In order to prevent harm from treatment de-escalation for such 
patients, biomarkers for high-risk patient identification among HPV-positive patients are 
needed. 
We analyzed antibody responses to non-viral cancer antigens for HPV-positive and HPV-
negative patients (n=362) in five independent cohorts treated at large European cancer 
centers. Antibodies to IMP-1 were associated with reduced overall survival in HPV-positive 
patients, and antibody responses to c-myc, MAGE-A1, MAGE-A4, and Rhodopsin E2 
(combined as ARhigh risk) in HPV-negative patients respectively. Our findings were validated 
in a multivariable cox proportional hazard model with bootstrapping (M=1000). In HPV-
positive and negative head and neck squamous cell carcinoma, antibody responses to cancer 
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Abstract 
Purpose: The identification of high-risk patients within Human Papillomavirus (HPV) 
positive and negative head and neck squamous cell carcinoma patients is needed for improved 
treatment and surveillance strategies. In this study, we set out to discover Antibody responses 
(AR) with prognostic impact in head and neck squamous cell carcinoma (HNSCC) stratified 
by HPV-status. 
Experimental Design: A fluorescent bead-based multiplex serology assay to 29 cancer 
antigens (16 cancer-testis antigens, 5 cancer-retina antigens, 8 oncogenes) and 29 HPV-
antigens was performed in samples of 362 HNSCC patients from five independent cohorts 
(153 HPV-positive, 209 HPV-negative). A multivariable cox proportional hazard model with 
bootstrapping (M=1000) was used for validation of prognostic antibody responses. 
Results: AR to any of the cancer antigens were found in 257/362 patients (71%). In HPV-
negative patients, antibody responses to  to c-myc, MAGE-A1, -A4 and Rhodopsin E2 
(combined as ARhigh risk) were significantly associated with shorter overall survival. In HPV-
positive patients antibody responses to IMP-1 were discovered as a negative prognostic 
factor. ARhigh risk (HR=1.76) and antibody responses to IMP-1 (HR=3.28) were confirmed as 
independent markers for a poor prognosis in a multivariable Cox proportional hazard model 
with bootstrapping (M=1000). 
Conclusion: We identified AR to cancer antigens that associate with a dismal prognosis in 
HNSCC patients beyond HPV-positive-status. ARhigh risk may be used to detect HPV-negative 
patients with an extraordinarily bad prognosis. Most importantly, AR to IMP-1 may serve as a 
marker for a subgroup of HPV-positive patients that present with a poor prognosis similar to 
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Introduction 
Globally, head and neck squamous cell carcinoma (HNSCC) is diagnosed in almost 900,000 
cases annually resulting in approximately 450,000 cancer deaths per year (1). Human 
papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma (OPSCC)(2) and 
head and neck cancer of unknown primary (CUP)(3) have been recognized as distinct entities 
of HNSCC causally associated with HPV.  Clinically, a significant prognostic advantage for 
HPV-positive OPSCC has been determined in numerous studies for different primary 
treatment strategies (4, 5). However, five year overall survival rates of 70-80% indicate the 
existence of a subgroup with a dismal prognosis within HPV-positive patients. To date, there 
is no robust biomarker to detect such patients.  
Cancer-antigens are immunogenic proteins or peptides that can be recognized by the immune 
system. Shared cancer antigens include germ-line antigens that are exclusively expressed in 
tumor tissue such as cancer-testis antigens (6, 7) or cancer-retina antigens (8), oncogenes 
overexpressed in cancer tissue such as p53 (9) and foreign antigens such as viral antigens 
(10). Whereas antibody responses (AR) to viral antigens can be used to identify HPV-positive 
patients (3, 11-14), AR to shared, non-viral antigens may play an important role as prognostic 
markers in both HPV-positive and HPV-negative HNSCC (15, 16). 
The aim of this study was to define the potential prognostic impact of such AR to cancer 
antigens in HNSCC patients stratified by HPV-status. 
 
Methods 
The study was performed in accordance with the EQUATOR Network CONSORT Guidelines 
for prognostic studies, namely the Reporting Recommendations for Tumor Marker Prognostic 
Studies (REMARK Guidelines) (17). 
Patients 
In this study, 362 patients with curative treatment for histologically diagnosed head and neck 
squamous cell carcinoma (HNSCC), an available serum or plasma sample taken prior to the 
initiation of treatment and written informed consent according to the Helsinki Declaration II 
were selected. Patients were treated per institutional guidelines at five large head and neck 
cancer centers, namely University Medical Centers Ulm, Heidelberg Leipzig (Germany), 
Padua (Italy) and St. Gallen (Switzerland) (Figure S1). The AJCC cancer staging manual 
version 7 was used for classification of TNM and disease stage. 
Human papilloma virus status 
HPV status was determined at each center according to institutional standards. For n=294 
patients, a multiplex HPV-DNA PCR (GP5+/GP6+ primers followed by Sanger sequencing 
for HPV typing as previously described (18)) and p16 immunohistochemistry (n=254) was 
performed. For n=146 patients, HPV E6*I mRNA status(19, 20) was available. Molecular 
HPV-status was considered positive if two of the following three parameters were positive: 
HPV-DNA of known high-risk types, HPV-16 E6*I RNA, p16 immunohistochemistry. All 
other combinations were considered HPV-negative. Molecular HPV-status showed a 
significant correlation with the results of HPV-serology (Pearson correlation coefficient = 
0.775, p<0.001). Thus, for patients lacking data for determination of the molecular HPV 
status, primarily non-oropharyngeal cancers, results from HPV-serology to high-risk types 
were used as a surrogate parameter resulting in a combined marker HPV (mol/ser). 
Research. 
on August 30, 2019. © 2019 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 23, 2019; DOI: 10.1158/1078-0432.CCR-19-1490 
Running Title: Prognostic impact of AR to cancer antigens in HNSCC 
 5 
Material 
Serum or plasma samples were prospectively collected prior to treatment initiation, aliquoted 
and stored at -20°C until use. Prospective sample collection was in accordance with local 
ethics committee approvals . 
Cancer-antigen serology 
Full-length proteins of selected cancer antigens were generated for multiplex serology as 
previously described (21-24). The cancer antigen panel is shown in Table 1.  
In brief, genes encoding for 16 cancer-testis antigens, 5 cancer-retina antigens, 8 oncogenes, 
29 HPV-antigens (from 8 high-risk HPV types) and two control antigens (JC and BK virus 
major capsid protein VP1) were cloned into the pGEX4T3 tag vector for expression in E. coli 
BL21 as fusion proteins with N-terminal glutathione-S-transferase (GST) and a small C-
terminal tagging epitope (tag) as previously described (23, 25). GST-tag fusion protein 
without insert was used to determine serological background. Anti-GST (GEHealthcare, 
Munich), anti-tag and anti-mouse HRP secondary antibodies (Dianova) were used to confirm 
full-length protein expression and protein integrity. 
Multiplex serology was performed as previously described (21-23, 25). For each antigen and 
bead set, 2500 glutathione-casein coated beads per sample were used and sera or plasma were 
measured at 1:1000 dilutions. Reporter fluorescence of the beads was determined with the 
Bio-Plex analyzer (BioRad) and expressed as MFI of at least 100 beads per set per well. 
Antigen-specific reactivity was calculated as the difference between antigen-MFI, GST-tag-
MFI and a blank. This value was used for further analyses. Cut-offs were determined 
graphically for non-viral antigens based on visual inspection of percentile plots (26). For viral 
antigens, cut-offs were available from previous studies (12). 
Statistics 
For statistical analysis, the SAMPL guidelines were respected (27). IBM SPSS statistics 
version 25.0 was used for statistical analysis unless indicated otherwise.  
Survival data were available for 360/362 patients. Overall survival (OS) was defined as the 
time interval from diagnosis until death. Disease-specific survival (DSS) was defined as the 
time interval from diagnosis until cancer-related death. Non-cancer related deaths were not 
counted as events for DSS. Survival analyses were performed and graphed with SPSS using 
the Kaplan-Meier method. Analyses with <5 patients in one of the groups analyzed were 
excluded from OS analysis. Groups were compared by log-rank-test. P-values <0.05 were 
considered significant, but corrections for multiple testing were performed to reduce statistical 
errors. Corrections for multiple testing were done using  Prism version 7.0c (GraphPad 
Software, Inc) with a false discovery rate (FDR) approach for each hypothesis using the two-
stage step up method of Benjamini, Krieger and Yekutieli (28). Given the exploratory nature 
of the study, a FDR of up to 15% was tolerated.  
Multivariable Cox proportional-hazards models were used to calculate hazard ratios (HR) and 
95% confidence intervals (CI) using R. We applied a bootstrap approach (M=1000) for 
variable selection (29). This method uses a nested selection procedure over all variable 
subsets and model comparison via Akaike information criterion to determine the most 
relevant variables, i.e. only the most frequent variables (>=70%) from all bootstrap 
replications. The following known prognostic markers were included in the multivariable 
analysis: T-status (T1-3, T4, CUP), N-status (N0, N+), stage (I, II, III, IV), HPV-status 
(mol/ser), smoking status (yes, no), primary treatment modality (surgical, non-surgical) and 
the primary site (Oropharynx, CUP, non-Oropharynx). In addition, all experimental markers 
that were significantly associated with survival in the whole cohort or stratified by HPV-
status were integrated into the model. 
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Results 
Patient characteristics of the cohort of 362 patients with HNSCC are presented in Table 2. 
The majority of patients had an oropharyngeal tumor, explaining the high rate of HPV-
positive patients (42.3%). A more detailed description of the non-oropharyngeal tumor 
patients is presented in supplementary Table S1. 
Among the 362 patients, 257 (71%) were seropositive for any of the 29 auto-antigens tested. 
Within the cohort 360 patients were evaluable for OS and 119 deaths occurred during the 
follow-up interval. Cause of death was available in 106/119 deaths (89%). Among those 106 
deaths 70 (66%) were cancer-related. 
To identify a prognostic impact associated with the presence of AR to certain antigens, 
overall survival (OS) was analyzed using the Kaplan-Meier method for each of the 
autoantigens. Patient groups containing <5 patients in one of the groups to be compared were 
excluded from the analysis. As shown in Figure S1,  2 AR, AR to IMP-1, MAGE-A1, -A3, -
A4, -A9, p53 Rhodopsin E2 and SSX-2 were associated with significantly shorter OS after 
correction for multiple testing with a FDR of 15%.  
The prognostic impact of HPV-status is well-known and can be considered the most 
important prognostic factor for HNSCC (4, 5, 13). In this cohort, the molecular HPV-status, 
as well as the serologic HPV-status (HPV-16 E6 antibodies, antibodies to high risk HPV-
types) and the combined surrogate marker HPV (mol/ser) resulted in consistent survival 
differences compared to the respective HPV-negative group (supplementary Figure S2). AR 
patterns and prevalences differed between HPV-positive and HPV-negative patients (not 
shown). Thus, OS analyses were then performed stratified by HPV-status (HPV mol/ser). 
Interestingly,  2AR to autoantigens, AR to c-myc, MAGE-A1, -A4 and Rhodopsin E2 were 
significantly associated with shorter OS in HPV-negative patients, but not in HPV-positive 
patients (Figure S3). On the other hand, AR to IMP-1 were significantly associated with 
shorter OS in HPV-positive patients (p>0.001), but not in HPV-negative patients (p=0.150) 
(Figure 1). Moreover, HPV-positive patients with AR to IMP-1 did not have a significantly 
different prognosis compared to HPV-negative patients (p=0.5). The results were corrected 
for multiple testing with a FDR of 15%. Results showed the lowest q-value for c-myc in 
HPV-negative patients (q<0.001) and for IMP-1 in HPV-positive patients (q<0.002).  
AR to any antigen with prognostic impact in HPV-negative patients, namely c-myc, MAGE-
A1, MAGE-A4 or Rhodopsin E2, were subsequently summarized under a new variable ARhigh 
risk (n=83). Presence of ARhigh risk was associated with significantly shorter survival in HPV-
negative patients compared to patients lacking ARhigh risk or HPV-positive patients (p<0.001; 
Figure 2). In HPV-positive patients, no statistical survival difference of patients with ARhigh 
risk compared to those without ARhigh risk (p=0.850) was found. The results for DSS were not 
substantially different (not shown). 
In order to address bias from other known prognostic markers, a multivariable Cox 
proportional hazard model was used. In addition to the known prognostic markers described 
in the methods section, all AR with a potential prognostic impact based on the OS analysis in 
the different patient groups (all, HPV-positive, HPV-negative) were tested, namely MAGE-
A3 AR (AR-, AR+), MAGE-A9 AR (AR-, AR+), p53 AR (AR-, AR+), SSX2 AR (AR-, 
AR+), ARhigh risk, IMP1 AR (AR-, AR+) and the number of AR (0-1, ≧2). In the final model, 
advanced T-category, ARhigh risk and AR to IMP-1 were associated with a significantly 
increased hazard ratio (HR), whereas HPV-positive status was associated with a significantly 
reduced HR (Cox proportional hazard model; Wald: p=6e-11). HR values for the four 
variables in the final model with the respective 95% confidence intervals, p-values and the 
number of positive bootstraps are listed in Table 3.  
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Discussion 
We were able to show a significant prognostic impact for shorter OS associated with several 
AR to cancer antigens, both agnostic of and stratified by HPV-status. The multivariable Cox 
proportional hazard models confirmed ARhigh risk and IMP-1 among T-category and HPV-
status (HPVmol/ser) as independent markers of a poor prognosis. Instead of arbitrarily dividing 
the cohort from the five centers into just one test and one validation cohort, we selected a 
bootstrap approach (M=1000) for variable selection (29). The benefit of this method is a 
nested selection procedure over all variable subsets. All models were compared via Akaike 
information criterion to determine the most relevant variables. Only the most frequent 
variables (>=70%) from all bootstrap replications were selected for the final model. ARhigh risk 
and IMP-1 were stably presented variables in the 1000 models tested. 
Thus, we have identified a serological marker each to detect patients at higher risk of death 
for HPV-negative patients (ARhigh risk) and for HPV-positive patients (IMP-1).  
IMP-1 (Insulin-like growth factor 2 mRNA-binding protein 1; IGF2BP1) is a mRNA binding 
protein that functions as a transcription factor and also belongs to the cancer-testis antigen 
family (30). By binding to mRNA it forms a protein mRNA complex which stabilizes the 
target RNA and enhances translation of protein e.g. of cmyc (31) or KRAS (32). It is 
considered to promote cell proliferation and tumorigenesis (31, 33, 34) and has been 
associated with a poor prognosis in neuroblastoma (35). Humoral immune responses to IMP-1 
have previously been described in ovarian cancer (30).  
Within the group of HPV-positive patients, a biomarker to identify those HPV-positive 
patients who have a prognosis comparable to HPV-negative patients is lacking. Smoking 
status has been reported as a prognostic marker for HPV-positive patients (4), but was not 
associated with a poor prognosis in our multivariable model. This may be due to different 
smoking habits in Germany. German HPV-positive patients tend to have a smoking history 
above 10 pack years in the median (36). In view of efforts do de-escalate treatment for HPV-
positive patients, it is highly important to detect high-risk patients.  
Recently, two treatment de-escalation trials for HPV-positive patients were published, both 
only using p16 for determination of HPV-status (37, 38). In contrast to the expected outcome, 
both trials failed to prove that cetuximab is less toxic than high-dose cisplatin. Instead 
exchanging cisplatin for cetuximab had a detrimental impact on OS.  
Alarmingly, in the clinical routine in the USA, some physicians are not recommending 
adjuvant treatment to surgically treated HPV-positive patients (39). To protect HPV-positive 
patients with a bad outcome from harm, the subgroup of patients with a poor prognosis needs 
to be identified, if a de-escalation of treatment for HPV-positive patients should be 
established in the future.  
Several other studies have associated AR to certain cancer antigens with detrimental or 
beneficial prognosis (22, 24, 40). In most studies and for most antigens, a negative prognostic 
impact- consistent with our results- was found. These findings indicate that humoral 
immunity to cancer antigens may be a poor surrogate marker for active cancer immunity, but 
rather an indirect measure of antigen expression as shown previously (40-43). At the same 
time, these patients may be candidates for antigen-specific immunotherapy which may 
improve the detrimental outcome. Cancer antigen serology may therefore identify patients 
who are at high risk of death, but who may benefit from immunotherapy (44). 
There are some limitations to our study: Patients were not treated within a prospective clinical 
trial with a defined treatment regimen. However, patients were treated at five large European 
cancer centers in line with international treatment guidelines. Due to the number of 
hypotheses tested, corrections for multiple testing were needed and performed. Some of the 
prognostic groups compared were rather small due to the diversity of antibody response 
patterns. However, the results for ARhigh risk and IMP-1 remained stable up to a FDR of 1%. 
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The multivariable Cox proportional hazard model with 1000 bootstraps also confirmed these 
two factors among T-category and HPV-status to be significantly correlated with OS. The 
prognostic impact of serologic antibodies detected at baseline is somewhat controversial (3, 
22, 24, 45, 46). Antibody levels and biological activity may change over the course of the 
disease. As such, cancer-antigen antibodies may represent an interesting biomarker during 
post-treatment surveillance. However, a prospective validation of these new markers, 
preferably in a randomized trial with samples taken over the course of treatment and follow-
up would be desirable. 
In conclusion, our results show that ARhigh risk may be used to identify patients with a dismal 
prognosis among HPV-negative patients and AR to IMP-1 among HPV-positive patients. AR 
to IMP-1 is a novel marker to detect HPV-positive patients who have a comparable prognosis 
to HPV-negative patients. In view of current strategies to de-escalate treatment for HPV-
positive patients (39) such patients are at risk and need to be identified.   
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Figure Legends: 
Figure 1: Overall survival of patients with antibody responses to IMP-1.  
Kaplan Meier plots are shown for Human papillomavirus (HPV) positive and HPV-negative 
patients with or without antibody responses (AR) to IMP-1. HPV+ / AR IMP-1+ patients 
(mean OS 41.2 months) had a much shorter overall survival than HPV+ / AR IMP-1- patients 
(mean OS 109.3 months, p<0.001). In fact, HPV+ / AR IMP-1+ patients (mean OS 41.2 
months) had a similar prognosis to HPV- / IMP-1- patients (mean OS 27.0 months, p=0.530) 
or HPV- / IMP-1+ patients (79.7 months, p=0.515).  
 
Figure 2: Overall survival of patients with antibody responses to ARhigh risk.  
Antibody responses (AR) to c-myc, MAGE-A1, -A4 or Rhodopsin E2 were summarized 
under the variable ARhigh risk. Kaplan Meier plots are shown for Human papillomavirus (HPV) 
positive and HPV-negative patients with or without antibody responses (ARhigh risk). 
HPV- / ARhigh risk patients (mean OS 36.5 months) had a significantly shorter OS than HPV-/ 
no ARhigh risk patients (mean OS 87.3 months, p<0.001), HPV+/ no ARhigh risk patients (mean 
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Tables 
Table 1: Cancer antigen panel for multiplex serology 
Cancer-Testis-Antigens 
(n=16)   
Cancer-Retina 
Antigens (n=5) Histone H2B 
HPV-31 (L1, E6, 
E7) 
MAGE-A1 SpanXa1 Arrestin HSP 70 
HPV-33 (L1, E6, 
E7) 
MAGE-A3 SSX2 Recoverin Ras 
HPV-35 (L1, E6, 
E7) 
MAGE-A4 SSX4 Rhodopsin C p53 




(IGF2BP1) Rhodopsin N pRb 
HPV-52 (L1, E6, 
E7) 
MAGE-C2 cTAGE 5a Rhodopsin E2 Survivin 
HPV-58 (L1, E6, 
E7) 
CT47  CAMEL 
Oncogenes (non-viral) 
(n=8) HPV-Antigens (n=29) 
Control Antigens 
(n=2) 
GAGE NY-ESO-1 c-myc 
HPV-16 (L1, E6, E7, E1, 
E2, E4) 
BK Virus Protein 
1 
LAGE OY-TES-1 cyclin D1 
HPV-18 (L1, E6, E7, E1, 
E2) 
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Table 2: Patient characteristics  by Primary Site (Oropharynx, CUP, Non-Oropharynx) 
  
Primary Site Total Cohort 
Oropharynx 
(54,9%) CUP (11.8%) 
Non-Oropharynx 
(44,0%) 
n % n % n % n % 
T 1 28 14,0% n.a. n.a. 22 18,0% 50 13,8% 
2 86 43,0% n.a. n.a. 32 26,2% 118 32,6% 
3 35 17,5% n.a. n.a. 29 23,8% 64 17,7% 
4 51 25,5% n.a. n.a. 39 32,0% 90 24,9% 
Missing 0 0,0% n.a. n.a. 0 0,0% 43 11,9% 
total 200 100% 40 100% 122 100% 362 100% 
N 0 41 20,5% 0 0,0% 61 50,0% 102 28,2% 
1 26 13,0% 15 37,5% 19 15,6% 60 16,6% 
2 125 62,5% 20 50,0% 36 29,5% 181 50,0% 
3 8 4,0% 4 10,0% 6 4,9% 18 5,0% 
Missing 0 0,0% 1 2,5% 0 0,0% 1 0,3% 
Total 200 100% 40 100% 122 100% 362 100% 
M 0 200 100,0% 40 100,0% 122 100,0% 362 100,0% 
Total 200 100% 40 100% 122 100% 362 100% 
Stage I 6 3,0% 0 0,0% 14 11,5% 20 5,5% 
II 17 8,5% 0 0,0% 17 13,9% 34 9,4% 
III 31 15,5% 15 37,5% 30 24,6% 76 21,0% 
IVA/B 146 73,0% 24 60,0% 61 50,0% 231 63,8% 
Missing 0 0,0% 1 2,5% 0 0,0% 1 0,3% 


















16,4% 154 42,5% 
Missing 0 0,0% 0 0,0% 0 0,0% 0 0,0% 
Total 200 100% 40 100% 122 100% 362 100% 
Treatment 
approach 
Surgical 148 74,0% 36 90,0% 100 82,0% 284 78,5% 
Non-surgical 52 26,0% 4 10,0% 20 16,4% 76 21,0% 
Missing 0 0,0% 0 0,0% 2 1,6% 2 0,6% 
Total 200 100% 40 100% 122 100% 362 100% 
Sex Male 151 75,5% 36 90,0% 99 81,1% 286 79,0% 
Female 49 24,5% 4 10,0% 23 18,9% 76 21,0% 
Total 200 100% 40 100% 122 100% 362 100% 
Smoking   Non-smoker 50 25,0% 8 20,0% 30 24,6% 88 24,3% 
Smoker 148 74,0% 30 75,0% 89 73,0% 267 73,8% 
Missing 2 1,0% 2 5,0% 3 2,5% 7 1,9% 
Total 200 100% 40 100% 122 100% 362 100% 
* Molecular HPV status was considered positive if two out of three diagnostic tests (HPV RNA, HPV DNA, 
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Table 3: Final multivariable Cox proporional hazard model based on 1000 bootstraps 
 
 HR 95% CI p-value positive bootstrap replicates 
T-status T1-3 1       
791 T4 1,750 1,158 2,644 0,008 
CUP 2,460 1,420 4,261 0,001 
HPV-status 
(mol/ser) 
HPV- 1     
<0,0001 1000 
HPV+ 0,340 0,222 0,521 
ARhigh risk AR- 1     
0,007 716 
AR+ 1,756 1,167 2,642 
IMP-1 AR AR- 1     
0,002 859 
AR+ 3,279 1,562 6,882 
Parameters in the model initially (1000 bootstraps): T-status (T1-3, T4, CUP), N-status (N0, N+), stage (I, 
II, III, IV), HPV-status (mol/ser), smoking status (yes, no), primary therapy (surgical, non-surgical), 
Primary site (Oropharynx,  CUP, non-Oropharynx), MAGE-A3 AR (AR-, AR+), MAGE-A9 AR (AR-, AR+), p53 
AR (AR-, AR+), SSX2 AR (AR-, AR+), AR HPV-negative, IMP1 AR (AR-, AR+), AR# (0-1, ≧2).  
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